Physician profile
Eric W Vincent
NPI 1871775742
$8,419.76
in general payments reported to CMS, 2019-2025
22 companies · $5,355 in 2025
The $5,355 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.54 · 2022: $747 · 2023: $755 · 2024: $1,518 · 2025: $5,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,818 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,550 · Travel and Lodging: $158 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,550.00 |
| Travel and Lodging | $158.20 |
| Education | $101.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $3,869.50 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $743.04 | 2022-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $488.45 | 2025 | Uzedy, Austedo Xr |
| Amgen INC. | $482.15 | 2022-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $453.09 | 2022-2025 | Wegovy, Ozempic |
| Vanda Pharmaceuticals INC. | $450.07 | 2024-2025 | Fanapt |
| Abbvie INC. | $380.22 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $277.50 | 2022-2024 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $238.97 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $152.63 | 2023-2025 | Tezspire, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.41 | 2022-2025 | Jardiance |
| Neurocrine Biosciences, INC. | $128.39 | 2025 | |
| Pfizer INC. | $121.50 | 2025 | |
| Axsome Therapeutics, INC. | $97.47 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $96.19 | 2023 | Nucala |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $86.66 | 2022 | |
| Idorsia Pharmaceuticals US INC | $53.65 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $48.64 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $36.17 | 2022 | |
| Sunovion Pharmaceuticals INC. | $31.51 | 2021 | |
| Shield Therapeutics INC | $28.07 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.48 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.